Author(s): Uyttenhove C, Sommereyns C, Théate I, Michiels T, Van Snick J
Excessive or inappropriate production of IL-17A has been reported in diseases such as rheumatoid arthritis, asthma, and multiple sclerosis. The potential clinical relevance of these correlations was suggested by the protective effects of anti-IL-17A monoclonal antibodies in various mouse disease models. However, the chronic nature of the corresponding human afflictions raises great challenges for Ab-based therapies. An alternative to passive Ab therapy is autovaccination. Covalent association of self-cytokines with foreign proteins has been reported to induce the production of antibodies capable of neutralizing the biological activity of the target cytokine. We recently reported that cross-linking of IL-17A to ovalbumin produced highly immunogenic complexes that induced long-lasting IL-17A-neutralizing antibodies. Vaccinated SJL mice were completely protected against experimental autoimmune encephalomyelitis (EAE) induced by proteolipid protein peptide (PLP 139-151), and a monoclonal anti-IL-17A Ab (MM17F3), derived from C57Bl/6 mice vaccinated against IL-17A-OVA, also prevented disease development. Here we report that this Ab also protects C57Bl/6 mice from myelin oligdendrocyte glycoprotein (MOG)-induced EAE. Histological analysis of brain sections of C57Bl/6 mice treated with MM17F3 showed a complete absence of inflammatory infiltrates and evidence for a marked inhibition of chemokine and cytokine messages in the spinal cord. These results further extend the analytical and therapeutic potential of the autovaccine procedure.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/17911448
Author(s): Hohlfeld R, Wekerle H
Author(s): Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM
Author(s): Matusevicius D, Kivisäkk P, He B, Kostulas N, Ozenci V, et al.
Author(s): Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, et al.
Author(s): Fontenot JD, Gavin MA, Rudensky AY
Author(s): Haas J, Hug A, Viehover A, Fritzsching B, Falk CS, et al.
Author(s): Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, et al.
Author(s): Arnon R, Sela M, Teitelbaum D
Author(s): Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, et al.
Author(s): Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, et al.
Author(s): Fridkis-Hareli M, Strominger JL
Author(s): Aharoni R, Teitelbaum D, Arnon R, Sela M
Author(s): Murphy KM, Reiner SL
Author(s): Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, et al.
Author(s): Paul WE, Seder RA
Author(s): Mosmann TR, Sad S
Author(s): Neuhaus O, Farina C, Wekerle H, Hohlfeld R
Author(s): Aharoni R, Teitelbaum D, Sela M, Arnon R
Author(s): Aharoni R, Eilam R, Domev H, Labunskay G, Sela M, et al.
Author(s): Chen M, Gran B, Costello K, Johnson K, Martin R, et al.
Author(s): Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R
Author(s): Kantengwa S, Weber MS, Juillard C, Benkhoucha M, Fellay B, et al.
Author(s): Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA
Author(s): Chen C, Liu X, Wan B, Zhang JZ
Author(s): Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA